EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) announced today that clinical testing will be permitted under an Investigational New Drug Application (IND) for ADL5747, a novel oral compound that targets the Delta opioid receptor. Adolor expects to initiate Phase 1 clinical testing in the first quarter of 2008.
